FDA Approves New U.S. Labeling For ISENTRESS® (Raltegravir)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, have announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS® (raltegravir) Film-coated Tablets, Merck's integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. The updated prescribing information now includes 240-week results from the STARTMRK study, the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-naïve adult patients with HIV-1 infection...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news